Plasma proenkephalin A and incident chronic kidney disease and albuminuria in the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort

By sjmartinez • January 11, 2024

Bullen AL, Katz R, Poursadrolah S, Short SAP, Long DL, Cheung KL, Sharma S, Al-Rousan T, Fregoso A, Schulte J, Gutierrez OM, Shlipak MG, Cushman M, Ix JH, Rifkin DE. Plasma proenkephalin A and incident chronic kidney disease and albuminuria in the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. BMC Nephrol. 2024 Jan 10;25(1):16. doi: 10.1186/s12882-023-03432-7. PMID: 38200454.

Tags: albuminuria, Biomarker, Chronic kidney disease, Nephrology, proenkephalin A, Publications, Veterans Administration

Follistatin Mitigates Atherosclerosis Through Activation of Arginine Metabolism and Adipose Browning

Dirakvand G, Pervin S, Villa B, Le C, Yohanna K, Grijalva V, Chattopadhyay A, Sinha SK, Reddy ST, Singh R. Follistatin Mitigates Atherosclerosis Through Activation[...]

Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study

Htoo PT, Cho H, Paik JM, Bykov K, Everett BM, Glynn RJ, Shay C, Schmedt N, Wexler DJ, Patorno E. Cardiovascular outcomes of empagliflozin-GLP-1RA combination[...]

Comparative Effectiveness of Lipid-Lowering Therapies in Increasing High-Density Lipoprotein Cholesterol Levels in Patients with Chronic Kidney Disease

Naim MAAZ, Thomas F, Streja E, Davis RL, Kalantar-Zadeh K, Sumida K, Kovesdy CP. Comparative Effectiveness of Lipid-Lowering Therapies in Increasing High-Density Lipoprotein Cholesterol Levels[...]